Use of valproate medicines in pregnancy is associated with a 40% risk of persistent neurodevelopmental disorders and a 10% risk of physical birth defects. The Pregnancy Prevention Programme will include a risk acknowledgment form to be completed and signed by the specialist prescriber and the patient in a review at least once a year. Ensure all women and girls (and their parent, caregiver, or responsible person, if necessary) are fully informed of the risks and the need to avoid exposure to valproate medicines in pregnancy.